Our Strategy

Excalibur has a top tier performance as a fund manager in the medical sciences sector. Its most recent fund (Fund III) was launched in 2002. It has already returned over 30% of Fund III's capital. It has had one trade exit at a multiple of more than 6x original investment and completed a merger of another company for 2x its original investment.

Excalibur will extend Excalibur Fund Managers' proven investment approach across the entire medical sciences sector; targeting companies active in market segments such as aesthetics, diagnostics, medical devices, speciality pharmaceuticals, surgical equipment, healthcare services, medical supply chain, wellness and laboratory and hospital supplies.

Excalibur will operate primarily in the UK and Europe identifying lower risk, high reward medical investment prospects but will also explore opportunities in Asia, Australia, and the Middle East.

The overall aim of Excalibur’s business is to build highly valuable and profitable medical companies and achieve significant returns at low risk for investors.